CLASS II ONGOING Drug recall · Reported 14 Oct 2026 · FDA Enforcement Report
Apothecary NAD+ Injection 200 mg/mL Sterile Multi-Dose Vial recalled
Apothecary Pharma is recalling Apothecary NAD+ Injection 200 mg/mL Sterile Multi-Dose Vial, distributed nationwide in the US. The recall was initiated on 24 Sep 2026 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0037-2027
- FDA event ID
- 99952
- Recalling firm
- Apothecary Pharma, Cary, NC
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- 24 Sep 2026
- FDA classified
- 8 Oct 2026
- Reported
- 14 Oct 2026
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Sterility
- Drug class
- Injectable & IV Drugs
Timeline
| 24 Sep 2026 | Recall initiated by company | |
| 8 Oct 2026 | Classified by FDA | +14 days |
| 14 Oct 2026 | Published in enforcement report | +6 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Lack of Assurance of Sterility
A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.
Product as listed by the FDA
Apothecary NAD+ Injection 200 mg/mL, 6 mL Sterile Multi-Dose Vial, Rx Only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC, 27513, NDC 85091-011-06.
Where it was distributed
Nationwide within the United States
Questions about this recall
Why was it recalled?
Lack of Assurance of Sterility
Which lots are affected?
Lot #: AP-202647, BUD 13-Oct-2026
Where was it sold?
Nationwide within the United States
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 21 Oct 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
Other products in this recall event
1 other product · FDA event 99952This product is part of a recall event; the main page for the event is Tirzepatide Injection, 18mg/mL Sterile Multi-Dose Vial recalled.
| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| CLASS II | Tirzepatide Injection, 18mg/mL Sterile Multi-Dose Vial recalled | Apothecary Pharma | Sterility | Nationwide |
More recalls from Apothecary Pharma
All 2| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Tirzepatide Injection, 18mg/mL Sterile Multi-Dose Vial recalled | Apothecary Pharma | Sterility | Nationwide |